CNTX Context Therapeutics Inc.
USHealthcareAs of 2026-07-10 16:00
Why CNTX matters now
Context Therapeutics Inc. (CNTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.65 with +9.82% on the session and $60.0M in market capitalization; recent performance reads 1-month -70.88% and YTD -57.01%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-8.7M, and EPS of $-0.09. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -56.5%.
The latest indexable market news headline is "Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.25; recent insider activity includes Lehr Martin A. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.15
P/S
0.00
EV/EBITDA
-0.09
DCF Value
$0.67
FCF Yield
-56.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.0%
ROA
-68.3%
ROIC
-82.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-8.7M | $-0.09 |
| Q4 2025 | $0.00 | $-13.0M | $-0.14 |
| FY 2025 | $0.00 | $-36.1M | $-0.38 |
| Q3 2025 | $0.00 | $-9.7M | $-0.10 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.25
Target (Median)
$5.25
Target Range
$4.50 - $6.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.61
Context Therapeutics Inc. (CNTX) is a biopharmaceutical firm in the clinical development stage, dedicated to advancing cancer treatments specifically for women in the United States. Its leading investigational therapy is onapristone extended release (ONA-XR). This compound functions as a potent and selective antagonist of the progesterone receptor, aiming to counteract the resistance often encountered with various cancer therapeutics, particularly anti-estrogen therapies, in hormone-dependent female cancers. The company is also progressing with CLDN6xCD3 bsAb, a bispecific monoclonal antibody designed to target both CD3 and Claudin 6 antigens. Its mechanism involves redirecting T-cell-mediated destruction towards malignant cells that express CLDN6. Furthermore, Context Therapeutics Inc. holds a collaboration and licensing agreement with Integral Molecular, Inc. This partnership focuses on the development of an anti-claudin 6 bispecific monoclonal antibody for the treatment of gynecologic cancers. Established in 2015, Context Therapeutics Inc. operates out of its headquarters in Philadelphia, Pennsylvania.